Advanced search
Publication Cover
Leukemia & Lymphoma Volume 47, 2006 - Issue 9
Submit an article Journal homepage
466
Views
18
CrossRef citations to date
0
Altmetric
Original

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Dr Steven W. Lane Department of Haematology, Princess Alexandra Hospital, School of Medicine, University of Queensland, Brisbane, AustraliaCorrespondence[email protected]
,
Julie Crawford Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
,
Melita Kenealy Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Australia
,
Gavin Cull Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
,
John F. Seymour Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Australia
,
H. Miles Prince Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Australia
,
Paula Marlton Department of Haematology, Princess Alexandra Hospital, School of Medicine, University of Queensland, Brisbane, Australia
,
Devinder Gill Department of Haematology, Princess Alexandra Hospital, School of Medicine, University of Queensland, Brisbane, Australia
&
Peter N. Mollee Department of Haematology, Princess Alexandra Hospital, School of Medicine, University of Queensland, Brisbane, Australia
 show all
Pages 1813-1817 | Received 15 Aug 2005, Accepted 25 Jan 2006, Published online: 01 Jul 2009

References

  • Pettengell R, Gurney H, Radford J A, Deakin D P, James R, Wilkinson P M, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436
  • Ozer H, Armitage J O, Bennett C L, Crawford J, Demetri G D, Pizzo P A, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: 3558–3585
  • Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30: 24–30
  • Green M D, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35
  • Holmes F A, O'Shaughnessy J A, Vukelja S, Jones S E, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731
  • Vose J M, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514–519
  • Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointer R, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1503–1508
  • Bosi A, Szer J, Kassis J, Sierra J, Desborough C, Buchanan K, et al. A multicentre, double-blind, randomized, phase 2 trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukaemia (AML). Blood 2004; 104: A866, Poster Session
  • Kantarjian H M, O'Brien S, Smith T L, Cortes J, Giles F J, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561
  • Thomas D A, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461–2470
  • Khouri I F, Romaguera J, Kantarjian H, Palmer J L, Pugh W C, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803–3809
  • Molineux G, Migdalska A, Haley J, Evans G S, Dexter T M. Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil. Blood 1994; 83: 3491–3499
  • Kwak L W, Halpern J, Olshen R A, Horning S J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963–977
  • Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol 2003; 30: 3–9
  • E-MIMS. St Leonards, Havas Medimedia International. 2005, Available on CD rom and also online at http://www.mims.com.au

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.